tlcd2 Antibody

What is the molecular function of TLCD2?

TLCD2 is a transmembrane protein that regulates membrane fluidity by limiting the levels of highly fluidizing long-chain polyunsaturated fatty acid-containing phospholipids. It acts by restricting the incorporation of LCPUFAs into phospholipids rather than affecting their synthesis or turnover . TLCD2 works in concert with its homolog TLCD1 to promote the incorporation of monounsaturated fatty acids (MUFAs) into phosphatidylethanolamines (PEs), particularly at the sn-1 position .

Where is TLCD2 predominantly expressed?

TLCD2 shows variable expression across tissues, with highest expression observed in heart, muscle, liver, small intestine, and fat tissues . This tissue-specific expression pattern suggests specialized roles in metabolically active tissues, particularly those involved in lipid metabolism.

What is the cellular localization of TLCD2?

TLCD2 primarily localizes to the endoplasmic reticulum (ER)/Golgi network, similar to other proteins involved in lipid remodeling . Research using HA-tagged TLCD2 in HeLa cells has confirmed this localization pattern. Additionally, TLCD2 interacts with mitochondria in an evolutionarily conserved manner, suggesting a role in regulating mitochondrial phospholipid composition .

What are the key specifications to consider when selecting a TLCD2 antibody?

When selecting a TLCD2 antibody, researchers should consider:

The antibody's epitope location is particularly important, as C-terminal targeting appears effective for human TLCD2 detection .

How can I validate TLCD2 antibody specificity?

Validating TLCD2 antibody specificity requires multiple approaches:

• Use Tlcd1/2 double-knockout (DKO) tissues or cells as negative controls

• Implement CRISPR/Cas9 or siRNA knockdown of TLCD2 in relevant cell lines

• Perform peptide competition assays using the immunizing peptide

• Compare detection patterns across multiple antibodies targeting different TLCD2 epitopes

• Verify protein size corresponds to the predicted molecular weight (28.7 kDa)

False positives may arise from cross-reactivity with TLCD1 due to sequence homology, making knockout controls particularly valuable .

What is the optimal protocol for Western blotting with TLCD2 antibody?

For optimal Western blotting results:

• Prepare protein lysates from tissues with known TLCD2 expression (liver, heart, muscle)

• Separate proteins using SDS-PAGE (10-12% gel recommended)

• Transfer to PVDF or nitrocellulose membrane

• Block with 5% non-fat dry milk in TBST

• Incubate with TLCD2 antibody at 1:1000 dilution in blocking buffer overnight at 4°C

• Wash with TBST (3-5 times, 5 minutes each)

• Incubate with appropriate HRP-conjugated secondary antibody

• Develop using chemiluminescence detection system

• Expected band: approximately 28.7 kDa

Include positive controls (liver tissue) and negative controls (TLCD2 knockout samples or primary antibody omission) .

How can I use TLCD2 antibody to investigate membrane fluidity regulation?

To investigate TLCD2's role in membrane fluidity:

• Establish cell models with modified TLCD2 expression:

  • siRNA knockdown of TLCD2

  • CRISPR/Cas9 knockout of TLCD2

  • Overexpression of HA-tagged TLCD2

• Challenge cells with membrane-rigidifying fatty acids (e.g., 200μM palmitic acid)

• Assess membrane fluidity using:

  • Fluorescence anisotropy measurements

  • Laurdan generalized polarization

  • Fluorescence recovery after photobleaching (FRAP)

• Perform lipidomic analysis on:

  • Total cellular lipid extracts

  • Isolated plasma membrane fractions

  • Mitochondrial fractions

• Use Western blotting with TLCD2 antibody to correlate protein levels with observed phenotypes .

Research has shown that TLCD2 knockdown protects against palmitic acid-induced membrane rigidification, with a particularly strong effect on increasing eicosapentaenoic acid (EPA) in phosphatidylcholines (PCs) .

Why might I observe multiple bands in Western blots using TLCD2 antibody?

Multiple bands in TLCD2 Western blots may result from:

• Post-translational modifications (glycosylation, phosphorylation)

• Protein degradation during sample preparation

• Cross-reactivity with TLCD1 (~31% sequence identity)

• Alternative splicing variants

• Non-specific binding

To resolve these issues:

• Use freshly prepared samples with protease inhibitors

• Optimize antibody concentration (start with 1:1000 dilution)

• Include Tlcd1/2 DKO samples as negative controls

• Perform peptide competition assays

• Try different blocking agents (BSA instead of milk)

How can I distinguish between TLCD1 and TLCD2 in my experiments?

Distinguishing between these homologous proteins requires:

• Using antibodies raised against unique epitopes specific to each protein

• Performing side-by-side knockdown experiments of each protein individually

• Using recombinant tagged versions (HA-TLCD1 vs. HA-TLCD2) in overexpression studies

• Analyzing expression patterns in tissues with differential expression

• Complementing antibody-based detection with RT-qPCR for mRNA expression

Research shows TLCD1 and TLCD2 have distinct effects on phospholipid species, with TLCD1 primarily affecting PEs and TLCD2 having stronger effects on PCs .

How can TLCD2 antibody be used to study mitochondrial interactions?

TLCD2's interaction with mitochondria can be investigated through:

• Co-immunoprecipitation experiments:

  • Immunoprecipitate with TLCD2 antibody

  • Analyze pulled-down proteins via mass spectrometry

  • Validate interactions with Western blotting for mitochondrial markers

• Subcellular fractionation and immunoblotting:

  • Isolate mitochondrial, ER, and plasma membrane fractions

  • Probe fractions with TLCD2 antibody

  • Quantify relative distribution across cellular compartments

• Immunofluorescence microscopy:

  • Co-stain cells with TLCD2 antibody and mitochondrial markers

  • Analyze colocalization using confocal microscopy

  • Quantify proximity using techniques like proximity ligation assay

Proteomic studies have revealed TLCD2 interacts with mitochondria in an evolutionarily conserved manner across species .

What is the role of TLCD2 in non-alcoholic steatohepatitis progression?

TLCD2 contributes to non-alcoholic steatohepatitis (NASH) progression through its effects on phospholipid composition:

• Tlcd1/2 DKO mice show:

  • Reduced levels of hepatic MUFA-containing PE species

  • Attenuated development of NASH compared to controls in dietary models

  • Post-transcriptional alterations in phospholipid composition

• Mechanistic studies using TLCD2 antibody can:

  • Track TLCD2 expression changes during disease progression

  • Identify protein interaction partners in healthy vs. diseased states

  • Evaluate TLCD2 as a potential therapeutic target

• In vitro models can assess:

  • TLCD2's impact on lipotoxicity pathways

  • Effects on inflammatory signaling in hepatocytes

  • Role in mitochondrial dysfunction during NASH development

How does TLCD2 mechanistically regulate phospholipid incorporation?

TLCD2 regulates phospholipid composition through several mechanisms:

• It limits LCPUFA incorporation into phospholipids, particularly affecting:

  • Incorporation of 18:2 (linoleic acid)

  • Incorporation of 18:3 (α-linolenic acid)

  • Incorporation of 20:5 (eicosapentaenoic acid) into PCs

• Time-course experiments using 13C-labeled LCPUFAs show:

  • TLCD2 knockdown causes increased incorporation of LCPUFAs within 6 hours

  • Effects are most pronounced in PE species after 24 hours

  • TLCD2 primarily limits formation of LCPUFA-containing phospholipids rather than promoting their turnover

• TLCD2 acts post-transcriptionally:

  • No alteration of hepatic transcriptome in Tlcd1/2 DKO mice

  • Similar alterations observed in red blood cells (which lack transcription)

  • Effects independent of changes in desaturase expression

What is the potential of TLCD2 as a therapeutic target?

Research suggests TLCD2 inhibition might have therapeutic applications:

• For metabolic disorders:

  • Tlcd1/2 DKO mice show attenuated NASH development

  • TLCD2 knockdown protects against palmitic acid-induced lipotoxicity

  • FLD-1 (C. elegans homolog) mutation has no obvious phenotype, suggesting inhibition may be well-tolerated

• For conditions involving membrane rigidity:

  • TLCD2 inhibition could normalize membrane fluidity in diabetic conditions

  • May have applications in treating AdipoR1 mutations causing retina defects

  • Could mitigate palmitic acid-induced apoptosis

• TLCD2 antibodies can facilitate:

  • Target validation studies

  • Pharmacodynamic biomarker development

  • Screening assays for inhibitor development

What is the relationship between TLCD2 and other membrane-regulating proteins?

TLCD2 functions within a network of membrane-regulating proteins:

• Interactions with adiponectin receptors:

  • TLCD2 knockdown suppresses membrane rigidification in AdipoR2 knockdown cells

  • TLCD2 knockdown normalizes ceramide levels in AdipoR2 knockdown cells challenged with palmitic acid

  • Functional relationship suggests coordinated regulation of membrane homeostasis

• Connections to desaturase pathways:

  • TLCD2 siRNA protects against potentiated rigidifying effects when FADS2 desaturase is knocked down

  • TLCD2 acts independently from desaturases

  • May represent a parallel pathway for membrane fluidity regulation

• Role in calcium channel regulation:

  • Published observations indicate TLCD1 facilitates the activity of calcium channels essential during neural plate development

  • Membrane composition effects extend to various cellular processes including insulin secretion, glucose transport, and TRPV channel activity